Glycemic effects and safety of L-Glutamine supplementation with or without sitagliptin in type 2 diabetes patients-a randomized study
Dorit Samocha-Bonet, Donald J Chisholm, Fiona M Gribble, Adelle C F Coster, Kevin H Carpenter, Graham R D Jones, Jens J Holst, Jerry R Greenfield, Dorit Samocha-Bonet, Donald J Chisholm, Fiona M Gribble, Adelle C F Coster, Kevin H Carpenter, Graham R D Jones, Jens J Holst, Jerry R Greenfield
Abstract
Background and aims: L-glutamine is an efficacious glucagon-like peptide (GLP)-1 secretagogue in vitro. When administered with a meal, glutamine increases GLP-1 and insulin excursions and reduces postprandial glycaemia in type 2 diabetes patients. The aim of the study was to assess the efficacy and safety of daily glutamine supplementation with or without the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin in well-controlled type 2 diabetes patients.
Methods: Type 2 diabetes patients treated with metformin (n = 13, 9 men) with baseline glycated hemoglobin (HbA1c) 7.1±0.3% (54±4 mmol/mol) received glutamine (15 g bd)+ sitagliptin (100 mg/d) or glutamine (15 g bd) + placebo for 4 weeks in a randomized crossover study.
Results: HbA1c (P = 0.007) and fructosamine (P = 0.02) decreased modestly, without significant time-treatment interactions (both P = 0.4). Blood urea increased (P<0.001) without a significant time-treatment interaction (P = 0.8), but creatinine and estimated glomerular filtration rate (eGFR) were unchanged (P≥0.5). Red blood cells, hemoglobin, hematocrit, and albumin modestly decreased (P≤0.02), without significant time-treatment interactions (P≥0.4). Body weight and plasma electrolytes remained unchanged (P≥0.2).
Conclusions: Daily oral supplementation of glutamine with or without sitagliptin for 4 weeks decreased glycaemia in well-controlled type 2 diabetes patients, but was also associated with mild plasma volume expansion.
Trial registration: ClincalTrials.gov NCT00673894.
Conflict of interest statement
Competing Interests: Carpenter KH, Coster ACF, and Jones GRD have nothing to declare; Chisholm DJ has been a board member for Astra Zeneca/Bristol Myer Squibb (Member/Chairman of Australian and International Advisory Board) and has received speaker honoraria from Astra Zeneca/Bristol Myers Squibb and MSD; Gribble FM is a board member of BioKier, consultant for Roche, and has received speaker honoraria from Novo Nordisk and Merck, and travel/accommodation expenses from Merck. Holst JJ is a consultant to NovoNordisk and holds grants from Novartis and Merck. Greenfield JR was a Principal Investigator on an Investigator-Initiated Studies Program grant from Merck and Co., awarded to the Garvan Institute of Medical Research, and Samocha-Bonet D was partly supported by this grant. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Figures
References
- Drucker DJ (2006) The biology of incretin hormones. Cell Metabolism 3: 153–165.
- Holst JJ, Vilsboll T, Deacon CF (2009) The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 297: 127–136.
- Nauck MA, Baller B, Meier JJ (2004) Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes. Diabetes 53 Suppl 3: S190–196.
- Thomas E, Habener JF (2010) Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis. Trend Endocrinol Metab 21: 59–68.
- Reimann F, Williams L, da Silva Xavier G, Rutter GA, Gribble FM (2004) Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells. Diabetologia 47: 1592–1601.
- Tolhurst G, Zheng Y, Parker HE, Habib AM, Reimann F, et al. (2011) Glutamine triggers and potentiates glucagon-like peptide-1 secretion by raising cytosolic Ca2+ and cAMP. Endocrinology 152: 405–413.
- Greenfield JR, Farooqi IS, Keogh JM, Henning E, Habib AM, et al. (2009) Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. Am J Clin Nutr 89: 106–113.
- Samocha-Bonet D, Wong O, Synnott EL, Piyaratna N, Douglas A, et al. (2011) Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients. J Nutr 141: 1233–1238.
- Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43: 535–539.
- Cohen RM, Franco RS, Khera PK, Smith EP, Lindsell CJ, et al. (2008) Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood 112: 4284–4291.
- Solis-Herrera C, Triplitt C, Garduno-Garcia JdJ, Adams J, DeFronzo RA, et al. (2013) Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes: A double-tracer study. Diabetes Care 36: 2756–2762.
- Novak F, Heyland DK, Avenell A, Drover JW, Su X (2002) Glutamine supplementation in serious illness: a systematic review of the evidence. Crit Care Med 30: 2022–2029.
- Heyland D, Drover J, Dhaliwal R (2006) Does the addition of glutamine to enteral feeds affect patient mortality? Crit Care Med 34: 2031–2032 author reply 2032.
- Andrews PJD, Avenell A, Noble DW, Campbell MK, Croal BL, et al. (2011) Randomised trial of glutamine, selenium, or both, to supplement parenteral nutrition for critically ill patients. Br Med J 342.
- Menge BA, Schrader H, Ritter PR, Ellrichmann M, Uhl W, et al. (2010) Selective amino acid deficiency in patients with impaired glucose tolerance and type 2 diabetes. Regul Pept 160: 75–80.
- Gleeson M (2008) Dosing and Efficacy of Glutamine Supplementation in Human Exercise and Sport Training. J Nutr 138: 2045S–2049S.
- Galera SC, Fechine F, Teixeira MJ, Branco Coelho ZC, de Vasconcelos RC, et al. (2010) The safety of oral use of l-glutamine in middle-aged and elderly individuals. Nutrition 26: 375–381.
- House JD, Pencharz PB, Ball RO (1994) Glutamine Supplementation to Total Parenteral Nutrition Promotes Extracellular Fluid Expansion in Piglets. J Nutr 124: 396–405.
Source: PubMed